In vivo evaluation of the influence of possible changes in the osteoclastogenesis process caused by the action of inflammatory drugs in rats with induced diabetes mellitus

The insertion of potentially inflammation-controllingmedications common ground among health professionals since their performance provides postoperative comfort to patients; they can be divided into two types, steroidal anti-inflammatory drugs, and non-steroidal anti-inflammatory drugs, each having its particularity regarding the site of action. Steroidal anti-inflammatories have their action initiated at the top of the inflammatory process, limiting the appearance of isoformsfrom local trauma, apart from the therapeutic advantages, they also present significant disadvantages such as the action on proteins responsible for bone formation and resorption. Otherwise, non-steroidal anti-inflammatory drugs have a lower level of action on the inflammatory process, which limits their therapeutic advantage to only one pathway, the cyclooxygenase, and it can cause a delay in tissue repair.In patients with Diabetes Mellitus their therapeutic effects are significant regarding possible changes in cutaneous and bone repair.The aim of this study was to evaluate in vivo the influence of 3 different types of anti-inflammatory drugs. The results showed that the action of anti-inflammatory drugs did not influence the osteogenesis process, therefore the systemic factor is the main responsible for the increase in the time of the beginning of bone neoformation.